TL-
What isn't often mentioned here is that TPM could be used to formulate a tamper and abuse resistant extended release ORAL opioid that would be at least as effective as any competitor's. Oxymorphone is an obvious candidate as one could postulate that the TPM's enhanced delivery could increase its oral bioavailablilty.
It's just that there isn't any point in entering that particular market with all the direct competition when TMPs advantages could be applied so much more effectively to a patch. But, that's not to say that long term, an oral product might not have a place in POH's pain protfolio.
oxymorphone trials begin, page-39
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $11.50K | 4.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 101422109 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 20872825 | 7 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |